ReviewExpert review of hematology2012
Treating venous thromboembolism in patients with cancer.
Review in Expert review of hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.The Cochrane database of systematic reviews · 2020Pooled it
- Effect of Cluster Nursing Based on Multidisciplinary Management Strategy on Perioperative Venous Thromboembolism in Patients with Gastrointestinal Cancers.Journal of multidisciplinary healthcare · 2025Article
- Cancer-Associated Thrombosis: A Taiwanese Perspective on Therapeutic Options with Focus on Non-Vitamin K Antagonist Oral Anticoagulants.Acta Cardiologica Sinica · 2023Review
- Early warning prevention and control strategies to reduce perioperative venous thromboembolism in patients with gastrointestinal cancer.World journal of clinical cases · 2022Article
- Cancer-Associated Thrombosis: A New Light on an Old Story.Diseases (Basel, Switzerland) · 2021Review
- Proteome Analysis of Urinary Biomarkers in Acute Hypercoagulable State Rat Model.Frontiers in molecular biosciences · 2021Article
- Silver nanoparticles promote procoagulant activity of red blood cells: a potential risk of thrombosis in susceptible population.Particle and fibre toxicology · 2019Article
- Biliverdin Reductase B Dynamics Are Coupled to Coenzyme Binding.Journal of molecular biology · 2018Article
- Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE.TH open : companion journal to thrombosis and haemostasis · 2017Article
- Cancer-associated thrombosis: an overview.Clinical Medicine Insights. Oncology · 2014Review
- Stroke and Cancer- A Complicated Relationship.Journal of neurology & translational neuroscienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Venous thromboembolism (VTE) is a major cause of morbidity and mortality among patients with cancer. Although much is known about the factors that contribute to VTE risk, pre-emptive therapy in high-risk populations is clearly indicated in only a few clinical situations. Low-molecular-weight heparin is still the recommended class of anticoagulants for cancer-associated VTE. Management of VTE in patients with renal failure, hemorrhagic brain metastases, thrombocytopenia and coagulopathy remains challenging with few safe and effective alternatives. Novel oral agents are currently being investigated and may play a role in the future in the treatment of cancer-associated VTE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.